October 11, 2025 a 07:43 pm
GILD: Fundamental Ratio Analysis - Gilead Sciences, Inc.
Gilead Sciences, Inc. operates as a leading biopharmaceutical company with a strong focus on tackling unmet medical needs globally. Their diverse product lineup and strategic partnerships position them favorably in the healthcare industry. While the stock shows robust fundamentals, potential investors should consider market volatility and sector trends.
Fundamental Rating
Gilead Sciences demonstrates stable fundamental performance with an overall score of 4, corresponding to an A- rating.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 1 | |
| Price to Earnings | 3 | |
| Price to Book | 1 |
Historical Rating
The historical ratings display consistency in core metrics, except for a noted difference in the overall score from previous assessments.
| Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-10-10 | 4 | 5 | 5 | 5 | 1 | 3 | 1 |
| Previous | 0 | 5 | 5 | 5 | 1 | 3 | 1 |
Analyst Price Targets
Analysts suggest a positive outlook with a consensus "Buy" rating and a median price target of $135, indicating potential upside from current levels.
| High | Low | Median | Consensus |
|---|---|---|---|
| $143 | $108 | $135 | $129.17 |
Analyst Sentiment
The majority of analysts recommend a "Buy" rating, signifying confidence in the company's growth trajectory and market position.
| Recommendation | Count | Distribution |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 34 | |
| Hold | 22 | |
| Sell | 1 | |
| Strong Sell | 0 |
Conclusion
Gilead Sciences, Inc. presents a compelling investment opportunity with robust fundamentals and strong analyst support, especially highlighted by consensus 'Buy' recommendations. While their pipeline and partnerships offer promising potential, investors should remain cognizant of the inherent risks in biopharmaceuticals such as regulatory changes and competitive pressures. Continuous evaluation of market positions and innovations will be vital for maintaining growth and shareholder value.